TY - JOUR
T1 - Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
AU - Ribi, Karin
AU - Luo, Weixiu
AU - Walley, Barbara A.
AU - Burstein, Harold J.
AU - Chirgwin, Jacquie
AU - Ansari, Rafat H.
AU - Salim, Muhammed
AU - van der Westhuizen, Andre
AU - Abdi, Ehtesham
AU - Francis, Prudence A.
AU - Chia, Stephen
AU - Harvey, Vernon J.
AU - Giobbie-Hurder, Anita
AU - Fleming, Gini F.
AU - Pagani, Olivia
AU - Di Leo, Angelo
AU - Colleoni, Marco
AU - Gelber, Richard D.
AU - Goldhirsch, Aron
AU - Coates, Alan S.
AU - Regan, Meredith M.
AU - Bernhard, Jürg
N1 - Funding Information:
KR, WL, BAW, HJB, JC, RHA, MS, AvW, EA, VJH, AGH, OP, AG, ASC, and JB have nothing to disclose. PAF reports personal fees from AstraZeneca, personal fees from Novartis, outside the submitted work; and Presentation of SOFT and TEXT trial results for Pfizer and Ipsen at overseas meeting without receiving honorarium. SC reports grants from NCIC, during the conduct of the study. GFF reports personal fees from Up To Date and Vaniam Group, non-financial support from Corcept, other from Merck, Syndax, 47 Inc, Sanofi, Astex EMD Sereno, Roche/Genentech, Syros, Tesaro, Iovance, Sanofi, Ssermonix, Incyte, Compugen and Abbvie, outside the submitted work. AD reports personal fees from AstraZeneca, personal fees from Bayer, personal fees from Celgene, personal fees from Daichii-Sankyo, personal fees from Eisai, personal fees from Genentech, personal fees from Genomic Health, personal fees from Ipsen, personal fees from Lilly, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Seattle Genetics, outside the submitted work. MC reports personal fees from AstraZeneca, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Novartis, personal fees from OBI Pharma, personal fees from Puma Biotechnology, personal fees from Celldex, outside the submitted work. RDG reports grants from Pfizer, grants from Ipsen, grants from AstraZeneca, during the conduct of the study; grants from Roche, grants from Merck, grants from Celgene, grants from Ferring, grants from Novartis, outside the submitted work. MMR reports grants and non-financial support from Pfizer, non-financial support and other from Ipsen, during the conduct of the study; grants and non-financial support from Research funding to the IBCSG (and/or provision of drug supply for clinical trials) from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, grants from Bayer, grants and personal fees from Bristol-Myers Squibb, outside the submitted work.
Funding Information:
SOFT and TEXT receive financial support for trial conduct from Pfizer, the International Breast Cancer Study Group, the US National Cancer Institute, the Breast Cancer Research Foundation (16-185, 17-187, 18-003), Ipsen, TerSera. Pfizer and Ipsen provided drug supply.
Funding Information:
Support for the coordinating group, IBCSG: Frontier Science and Technology Research Foundation, Swiss Group for Clinical Cancer Research (SAKK), Cancer Research Switzerland, Oncosuisse, Cancer League Switzerland, Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK). Grant support of cooperative groups: Breast Cancer Trials Australia & New Zealand [NHMRC 351161, 510788 and 1105058]; Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) on behalf of the National Cancer Research Institute Breast Clinical Studies Group United Kingdom (NCRI-BCSG—ICR-CTSU Partnership) [Cancer Research UK CRUKE/03/022, CRUKE/03/023, A15955; National Institute for Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre; and National Institute for Health Research/Cambridge Biomedical Research Centre; Alliance for Clinical Trials in Oncology [US NIH U10CA180821]; SWOG [US NIH CA32102]; ECOG-ACRIN Cancer Research Group [US NIH CA21115, CA16116]; NRG Oncology [US NIH grant numbers U10CA180868, U10CA180822, UG1CA189867]; Canadian Cancer Trials Group [US NIH CA077202; and Canadian Cancer Society Research Institute 015469, 021039].
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Purpose: Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials. Methods: A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years. Results: Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point. Conclusion: Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.
AB - Purpose: Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials. Methods: A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years. Results: Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point. Conclusion: Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.
KW - Breast cancer
KW - Depression
KW - Endocrine treatment
KW - Sexual problems
KW - Treatment-induced symptoms
UR - http://www.scopus.com/inward/record.url?scp=85083058214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083058214&partnerID=8YFLogxK
U2 - 10.1007/s10549-020-05622-5
DO - 10.1007/s10549-020-05622-5
M3 - Article
C2 - 32274665
AN - SCOPUS:85083058214
VL - 181
SP - 347
EP - 359
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 2
ER -